肺结核无处不在，肺结核无处不在。意大利首例BPaL治疗前广泛耐药结核病病例：跨境合作的挑战和机遇。

IF 2.3 4区医学 Q3 INFECTIOUS DISEASES

Microbial drug resistance Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI:10.1089/mdr.2024.0045

Giovanni Fumagalli, Niccolò Riccardi, Gaia Catalano, Maurizio Ferrarese, Alice Claudia Repossi, Luigi R Codecasa

{"title":"肺结核无处不在，肺结核无处不在。意大利首例BPaL治疗前广泛耐药结核病病例：跨境合作的挑战和机遇。","authors":"Giovanni Fumagalli, Niccolò Riccardi, Gaia Catalano, Maurizio Ferrarese, Alice Claudia Repossi, Luigi R Codecasa","doi":"10.1089/mdr.2024.0045","DOIUrl":null,"url":null,"abstract":"Even if in the past years new effective, safe, and orally administrable drugs are available to create shorter regimens, drug-resistant (DR) tuberculosis (TB) treatment remains a critical issue and a major challenge faced by clinicians worldwide. We present the first case of transborder pulmonary pre-extensively drug-resistant (pre-XDR)-TB treated in Italy with the bedaquiline-pretomanid-linezolid regimen. Diagnosis and treatment were started in Ukraine, and, after a month of treatment, due to the Russo-Ukrainian war, the patient moved to Italy, where the diagnosis was confirmed both by genotypic and phenotypic drug susceptibility tests, and treatment continued. In this short report, we highlight challenges and future opportunities to improve the clinical management of patient with DR-TB.","PeriodicalId":18701,"journal":{"name":"Microbial drug resistance","volume":" ","pages":"12-15"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration.\",\"authors\":\"Giovanni Fumagalli, Niccolò Riccardi, Gaia Catalano, Maurizio Ferrarese, Alice Claudia Repossi, Luigi R Codecasa\",\"doi\":\"10.1089/mdr.2024.0045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Even if in the past years new effective, safe, and orally administrable drugs are available to create shorter regimens, drug-resistant (DR) tuberculosis (TB) treatment remains a critical issue and a major challenge faced by clinicians worldwide. We present the first case of transborder pulmonary pre-extensively drug-resistant (pre-XDR)-TB treated in Italy with the bedaquiline-pretomanid-linezolid regimen. Diagnosis and treatment were started in Ukraine, and, after a month of treatment, due to the Russo-Ukrainian war, the patient moved to Italy, where the diagnosis was confirmed both by genotypic and phenotypic drug susceptibility tests, and treatment continued. In this short report, we highlight challenges and future opportunities to improve the clinical management of patient with DR-TB.\",\"PeriodicalId\":18701,\"journal\":{\"name\":\"Microbial drug resistance\",\"volume\":\" \",\"pages\":\"12-15\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbial drug resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/mdr.2024.0045\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial drug resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/mdr.2024.0045","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

即使在过去几年中有了新的有效、安全且可口服的药物来缩短治疗方案，耐药结核病治疗仍然是世界各地临床医生面临的一个关键问题和重大挑战。我们提出了第一例跨界肺前广泛耐药（前xdr）结核在意大利治疗与贝达喹啉-pretomanid-利奈唑胺方案。诊断和治疗在乌克兰开始，在治疗一个月后，由于俄罗斯-乌克兰战争，患者转移到意大利，在那里通过基因型和表型药物敏感性试验证实了诊断，并继续治疗。在这份简短的报告中，我们强调了改善耐药结核病患者临床管理的挑战和未来机遇。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

TB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration.

Even if in the past years new effective, safe, and orally administrable drugs are available to create shorter regimens, drug-resistant (DR) tuberculosis (TB) treatment remains a critical issue and a major challenge faced by clinicians worldwide. We present the first case of transborder pulmonary pre-extensively drug-resistant (pre-XDR)-TB treated in Italy with the bedaquiline-pretomanid-linezolid regimen. Diagnosis and treatment were started in Ukraine, and, after a month of treatment, due to the Russo-Ukrainian war, the patient moved to Italy, where the diagnosis was confirmed both by genotypic and phenotypic drug susceptibility tests, and treatment continued. In this short report, we highlight challenges and future opportunities to improve the clinical management of patient with DR-TB.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Microbial drug resistance 医学-传染病学

CiteScore

6.00

自引率

3.80%

发文量

118

审稿时长

6-12 weeks

期刊介绍： Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global spread and threat of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community. The Journal addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance. MDR provides a multidisciplinary forum for peer-reviewed original publications as well as topical reviews and special reports. MDR coverage includes: Molecular biology of resistance mechanisms Virulence genes and disease Molecular epidemiology Drug design Infection control.